Literature DB >> 28479277

Selectivity of major isoquinoline alkaloids from Chelidonium majus towards telomeric G-quadruplex: A study using a transition-FRET (t-FRET) assay.

Sakineh Kazemi Noureini1, Hosein Esmaeili2, Farzane Abachi2, Soraia Khiali3, Barira Islam4, Martyna Kuta5, Ali A Saboury6, Marcin Hoffmann5, Jiri Sponer7, Gary Parkinson3, Shozeb Haider8.   

Abstract

BACKGROUND: Natural bioproducts are invaluable resources in drug discovery. Isoquinoline alkaloids of Chelidonium majus constitute a structurally diverse family of natural products that are of great interest, one of them being their selectivity for human telomeric G-quadruplex structure and telomerase inhibition.
METHODS: The study focuses on the mechanism of telomerase inhibition by stabilization of telomeric G-quadruplex structures by berberine, chelerythrine, chelidonine, sanguinarine and papaverine. Telomerase activity and mRNA levels of hTERT were estimated using quantitative telomere repeat amplification protocol (q-TRAP) and qPCR, in MCF-7 cells treated with different groups of alkaloids. The selectivity of the main isoquinoline alkaloids of Chelidonium majus towards telomeric G-quadruplex forming sequences were explored using a sensitive modified thermal FRET-melting measurement in the presence of the complementary oligonucleotide CT22. We assessed and monitored G-quadruplex topologies using circular dichroism (CD) methods, and compared spectra to previously well-characterized motifs, either alone or in the presence of the alkaloids. Molecular modeling was performed to rationalize ligand binding to the G-quadruplex structure.
RESULTS: The results highlight strong inhibitory effects of chelerythrine, sanguinarine and berberine on telomerase activity, most likely through substrate sequestration. These isoquinoline alkaloids interacted strongly with telomeric sequence G-quadruplex. In comparison, chelidonine and papaverine had no significant interaction with the telomeric quadruplex, while they strongly inhibited telomerase at transcription level of hTERT. Altogether, all of the studied alkaloids showed various levels and mechanisms of telomerase inhibition.
CONCLUSIONS: We report on a comparative study of anti-telomerase activity of the isoquinoline alkaloids of Chelidonium majus. Chelerythrine was most effective in inhibiting telomerase activity by substrate sequesteration through G-quadruplex stabilization. GENERAL SIGNIFICANCE: Understanding structural and molecular mechanisms of anti-cancer agents can help in developing new and more potent drugs with fewer side effects. Isoquinolines are the most biologically active agents from Chelidonium majus, which have shown to be telomeric G-quadruplex stabilizers and potent telomerase inhibitors.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Berberine; Chelerythrine; Chelidonine; G-quadruplex; Papaverine; Sanguinarine; Telomerase; Transition-FRET

Mesh:

Substances:

Year:  2017        PMID: 28479277     DOI: 10.1016/j.bbagen.2017.05.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta Gen Subj        ISSN: 0304-4165            Impact factor:   3.770


  10 in total

1.  Molecular Recognition of the Hybrid-2 Human Telomeric G-Quadruplex by Epiberberine: Insights into Conversion of Telomeric G-Quadruplex Structures.

Authors:  Clement Lin; Guanhui Wu; Kaibo Wang; Buket Onel; Saburo Sakai; Yong Shao; Danzhou Yang
Journal:  Angew Chem Int Ed Engl       Date:  2018-07-18       Impact factor: 15.336

Review 2.  Interaction of the putative anticancer alkaloid chelerythrine with nucleic acids: biophysical perspectives.

Authors:  Anirban Basu; Gopinatha Suresh Kumar
Journal:  Biophys Rev       Date:  2020-10-31

3.  Research Status and Hotspots of Anticancer Natural Products Based on the Patent Literature and Scientific Articles.

Authors:  Junkai Shen; Jiahuan Li; Peiming Yu; Gangjun Du
Journal:  Front Pharmacol       Date:  2022-06-17       Impact factor: 5.988

Review 4.  Rediscovery of Traditional Plant Medicine: An Underestimated Anticancer Drug of Chelerythrine.

Authors:  Nianzhi Chen; Yulin Qi; Xiao Ma; Xiaolin Xiao; Qingsong Liu; Ting Xia; Juyi Xiang; Jinhao Zeng; Jianyuan Tang
Journal:  Front Pharmacol       Date:  2022-06-01       Impact factor: 5.988

5.  Natural Product Library Screens Identify Sanguinarine Chloride as a Potent Inhibitor of Telomerase Expression and Activity.

Authors:  Siyu Yan; Song Lin; Kexin Chen; Shanshan Yin; Haoyue Peng; Nanshuo Cai; Wenbin Ma; Zhou Songyang; Yan Huang
Journal:  Cells       Date:  2022-04-28       Impact factor: 7.666

6.  Terpenes from essential oils and hydrolate of Teucrium alopecurus triggered apoptotic events dependent on caspases activation and PARP cleavage in human colon cancer cells through decreased protein expressions.

Authors:  Fatma Guesmi; Amit K Tyagi; Sahdeo Prasad; Ahmed Landoulsi
Journal:  Oncotarget       Date:  2018-08-17

7.  Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells.

Authors:  Fang-Jie Hou; Li-Xiao Guo; Kai-Yan Zheng; Jun-Na Song; Qian Wang; Yu-Guang Zheng
Journal:  Onco Targets Ther       Date:  2019-08-19       Impact factor: 4.147

Review 8.  Greater Celandine's Ups and Downs-21 Centuries of Medicinal Uses of Chelidonium majus From the Viewpoint of Today's Pharmacology.

Authors:  Sylwia Zielińska; Anna Jezierska-Domaradzka; Magdalena Wójciak-Kosior; Ireneusz Sowa; Adam Junka; Adam M Matkowski
Journal:  Front Pharmacol       Date:  2018-04-11       Impact factor: 5.810

9.  Telomere shortening in breast cancer cells (MCF7) under treatment with low doses of the benzylisoquinoline alkaloid chelidonine.

Authors:  Sakineh Kazemi Noureini; Leili Fatemi; Michael Wink
Journal:  PLoS One       Date:  2018-10-03       Impact factor: 3.240

10.  Effect of Protoberberine-Rich Fraction of Chelidonium majus L. on Endometriosis Regression.

Authors:  Alicja Warowicka; Badr Qasem; Anna Dera-Szymanowska; Maria Wołuń-Cholewa; Patryk Florczak; Nikodem Horst; Marta Napierała; Krzysztof Szymanowski; Łukasz Popenda; Grażyna Bartkowiak; Ewa Florek; Anna Goździcka-Józefiak; Piotr Młynarz
Journal:  Pharmaceutics       Date:  2021-06-23       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.